Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
COVID-19 Serological Testing
Carrier State
/ epidemiology
Chest Pain
/ epidemiology
Child
Child, Preschool
Contact Tracing
Cough
/ epidemiology
Critical Illness
Disease Progression
Dyspnea
/ epidemiology
Female
Fever
/ epidemiology
Humans
Infant
Infant, Newborn
Italy
/ epidemiology
Male
Middle Aged
Pharyngitis
/ epidemiology
Quarantine
Risk Factors
SARS-CoV-2
Severity of Illness Index
Tachypnea
/ epidemiology
Young Adult
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
entrez:
10
3
2021
pubmed:
11
3
2021
medline:
19
3
2021
Statut:
epublish
Résumé
Solid estimates of the risk of developing symptoms and of progressing to critical disease in individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are key to interpreting coronavirus disease 2019 (COVID-19) dynamics, identifying the settings and the segments of the population where transmission is more likely to remain undetected, and defining effective control strategies. To estimate the association of age with the likelihood of developing symptoms and the association of age with the likelihood of progressing to critical illness after SARS-CoV-2 infection. This cohort study analyzed quarantined case contacts, identified between February 20 and April 16, 2020, in the Lombardy region of Italy. Contacts were monitored daily for symptoms and tested for SARS-CoV-2 infection, by either real-time reverse transcriptase-polymerase chain reaction using nasopharyngeal swabs or retrospectively via IgG serological assays. Close contacts of individuals with laboratory-confirmed COVID-19 were selected as those belonging to clusters (ie, groups of contacts associated with an index case) where all individuals were followed up for symptoms and tested for SARS-CoV-2 infection. Data were analyzed from February to June 2020. Close contact with individuals with confirmed COVID-19 cases as identified by contact tracing operations. Age-specific estimates of the risk of developing respiratory symptoms or fever greater than or equal to 37.5 °C and of experiencing critical disease (defined as requiring intensive care or resulting in death) in SARS-CoV-2-infected case contacts. In total, 5484 case contacts (median [interquartile range] age, 50 [30-61] years; 3086 female contacts [56.3%]) were analyzed, 2824 of whom (51.5%) tested positive for SARS-CoV-2 (median [interquartile range] age, 53 [34-64] years; 1604 female contacts [56.8%]). The proportion of infected persons who developed symptoms ranged from 18.1% (95% CI, 13.9%-22.9%) among participants younger than 20 years to 64.6% (95% CI, 56.6%-72.0%) for those aged 80 years or older. Most infected contacts (1948 of 2824 individuals [69.0%]) did not develop respiratory symptoms or fever greater than or equal to 37.5 °C. Only 26.1% (95% CI, 24.1%-28.2%) of infected individuals younger than 60 years developed respiratory symptoms or fever greater than or equal to 37.5 °C; among infected participants older than 60 years, 6.6% (95% CI, 5.1%-8.3%) developed critical disease. Female patients were 52.7% (95% CI, 24.4%-70.7%) less likely than male patients to develop critical disease after SARS-CoV-2 infection. In this Italian cohort study of close contacts of patients with confirmed SARS-CoV-2 infection, more than one-half of individuals tested positive for the virus. However, most infected individuals did not develop respiratory symptoms or fever. The low proportion of children and young adults who developed symptoms highlights the possible challenges in readily identifying SARS-CoV-2 infections.
Identifiants
pubmed: 33688964
pii: 2777314
doi: 10.1001/jamanetworkopen.2021.1085
pmc: PMC7948061
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e211085Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Elife. 2020 Aug 24;9:
pubmed: 32831176
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Nat Commun. 2021 Mar 9;12(1):1533
pubmed: 33750783
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234
pubmed: 36340059
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
MMWR Morb Mortal Wkly Rep. 2020 Aug 07;69(31):1023-1025
pubmed: 32759921
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234117
Euro Surveill. 2020 Aug;25(31):
pubmed: 32762797
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Clin Infect Dis. 2020 Nov 19;71(16):2132-2138
pubmed: 32442265
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404